Skip to main content
Mohammad Maher Abdul Hay, MD, Oncology, New York, NY

Mohammad MaherAbdul HayMD

Oncology New York, NY

Hematologic Oncology

Director, Clinical Leukemia Program Medical Director KP18 Associate Professor of Medicine at NYU Blood and Bone Marrow Transplant Program

Dr. Abdul Hay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Abdul Hay's full profile

Already have an account?

  • Office

    240 E 38th St
    # Laura
    New York, NY 10016
    Phone+1 646-501-4818
    Fax+1 646-754-9844

Summary

  • Dr. Mohammad Maher Abdul Hay is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including NYC Health + Hospitals / Bellevue and NYU Langone Hospitals. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 13 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and bone marrow transplantation.

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2012
  • University at Buffalo
    University at BuffaloResidency, Internal Medicine, 2006 - 2009
  • University of Illinois College of Medicine
    University of Illinois College of MedicinePost-Doctoral Fellowship, 2005 - 2006
  • American University of Beirut Faculty of Medicine
    American University of Beirut Faculty of MedicineClass of 2004

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2012 - 2025
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

Abstracts/Posters

  • Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory ...
    Maher Abdul-Hay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Professional Memberships